Many immune-mediated diseases are at least in part the result of hyper-proliferation of immune cells, a phenomenon known as lymphoproliferation. Lymphoproliferative diseases include systemic lupus erythematosus (lupus), autoimmune lymphoproliferative syndrome, Waldenstrom’s macroglobulinemia, Wiskott-Aldrich syndrome, myelodysplastic syndromes, and post-transplant lymphoproliferative disorder (PTLD).
PTLD is a serious condition characterized by increased immune cell replication following a solid organ transplant. The disease can be fatal and is often poorly responsive to currently available therapy.
PTLD and other lymphoproliferative disorders are caused in part by excessive activity of the chaperome, which leads to aberrant stimulation of immune cellular replication. Aldeyra’s chaperome inhibitor product candidates are being developed for the potential treatment of PTLD and related diseases.